ArticleCurrent infectious disease reports2010
Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: an emerging fungal disease.
Article in Current infectious disease reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 35 citations in OpenAlex.
- Diagnostic criteria for invasive pulmonary aspergillosis in COPD patients.American journal of respiratory and critical care medicine · 2026Article
- Prognostic factors and outcomes of invasive pulmonary aspergillosis, a retrospective hospital-based study.PeerJ · 2024Article
- Nanotechnology-based drug delivery systems for control of microbial biofilms: a review.International journal of nanomedicine · 2018Review
- Development of Aspergillosis in a cohort of non-neutropenic, non-transplant patients colonised by Aspergillus spp.BMC infectious diseases · 2017Article
- Article
- Aspergillus infections in transplant and non-transplant surgical patients.Surgical infections · 2014Article
- Virulence and thrombocyte affectation of two Aspergillus terreus isolates differing in amphotericin B susceptibility.Medical microbiology and immunology · 2013Article
- Assessment of the significance of respiratory culture of Aspergillus in the non-neutropenic patient. A critique of published diagnostic criteria.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2013Article
- Therapeutic drug monitoring in voriconazole-associated hyponatremia.Medical mycology case reports · 2013Article
- Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome.Scientifica · 2013Review
- Invasive Aspergillus infections in hospitalized patients with chronic lung disease.Infection and drug resistance · 2013Article
- Repeated Aspergillus isolation in respiratory samples from non-immunocompromised patients not selected based on clinical diagnoses: colonisation or infection?BMC infectious diseases · 2012Article
- The performance of real-time PCR, galactomannan, and fungal culture in the diagnosis of invasive aspergillosis in ventilated patients with chronic obstructive pulmonary disease (COPD).Mycopathologia · 2012Article
- Role of galactomannan determinations in bronchoalveolar lavage fluid samples from critically ill patients with chronic obstructive pulmonary disease for the diagnosis of invasive pulmonary aspergillosis: a prospective study.Critical care (London, England) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive pulmonary aspergillosis (IPA) is a necrotizing pneumonia caused by airborne opportunistic fungi of Aspergillus species. Patients with advanced-stage chronic obstructive pulmonary disease (COPD) have emerged to be at risk for IPA as a result of the overall improvement of long-term management of the disease. IPA is among the most severe infectious event that may occur during the course of COPD resulting from profound immune impairment and associated with poor outcome. Many aspects of the development of IPA in COPD patients differ from hematologic patients, explaining various patterns of IPA in an expanded population of immunocompromised patients. Therefore, it is legitimate to focus on the literature-based data available regarding the factors involved in the development of IPA in this setting as well as the use and interpretation of diagnosis criteria, and the treatment options.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.